Article: A-119 A PATIENT WITH A TYPE 2 CB VON WILLEBRAND DISEASE: LABORATORY DIAGNOSIS AND RESPONSE TO DESMOPRESSIN

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma